Michael Morse, MD, MHS, FACP is Professor of Medicine in the Division of Medical Oncology at Duke University Medical Center. His clinical expertise focus on management of GI malignancies and melanoma. His research expertise include the development of targeted therapies and immunotherapies for cancer.
Dr Morse has published extensively on immunotherapy, targeted therapies, and GI malignancies, including textbooks on cancer vaccines and liver tumors. He is a national speaker on these topics and has collaborated on the generation of educational materials in GI oncology and immunotherapy. He is Editor for Current Opinions in Biologic Therapies and Associate Editor for the Journal of Clinical Investigation and Clinical Cancer Research.
His peer-reviewed funding has included that of project principal investigator in an NCI-funded program project grant, R21 grants, grants from the Department of Defense, and Komen Foundation. He has been principal investigator of a number of investigator-initiated and industry-supported phase I and II clinical trials of cancer immunotherapy and therapies for GI malignancies.
He is a member of AACR, ASCO, the American Society for Clinical Investigation, the American College of Physicians, and the American College of Surgeons Oncology Group.
Dr. Morse has moderated and participated in numerous advisory boards and consulted for pharmaceutical companies in his field of GI Oncology.